India
Dr Reddy's gets DCGI nod for Zytorvi, a new immunotherapy for esophageal cancer
India's drug regulator has cleared toripalimab as a first-line treatment for advanced esophageal squamous cell carcinoma, the most common form of the disease in the country.

India's drug regulator has approved a new immunotherapy option for people with advanced esophageal cancer. Dr Reddy's Laboratories said on Wednesday, October 21, that the Drugs Controller General of India (DCGI) has cleared Zytorvi (toripalimab) for first-line use in advanced esophageal squamous cell carcinoma, or ESCC.
The approval covers adults whose cancer cannot be removed by surgery, has come back, or has spread. Zytorvi is to be given along with two chemotherapy drugs, cisplatin and paclitaxel, the company said in a release.
This is the second use for which Zytorvi has been approved in India. It was earlier cleared for nasopharyngeal carcinoma, a cancer that starts at the back of the nose and throat.
The company says ESCC makes up about 80 per cent of all esophageal cancer cases in India, so the approval is aimed at a large share of patients with this disease. Dr Reddy's says it wants to widen access to immunotherapy at the very start of treatment.
Toripalimab is a monoclonal antibody. It attaches to a protein called PD-1 on immune cells and stops it from interacting with PD-L1 and PD-L2. In simple terms, this helps T-cells, a key part of the immune system, keep working against cancer cells.
The approval is backed by the Phase 3 JUPITER-06 trial. According to the company, adding toripalimab to paclitaxel and cisplatin cut the risk of the disease getting worse or of death by 42 per cent, compared with chemotherapy alone. In the final overall survival analysis, patients on the combination lived a median of 17.7 months, against 12.9 months for those on chemotherapy only.
Dr Reddy's holds the rights to sell toripalimab in 21 countries under a 2023 agreement with Junshi Biosciences. The figures above come from the company's own release. Details on pricing and when the drug will reach hospitals were not part of the announcement. Patients should speak to their oncologist about whether this treatment suits them. Read the original report here.